Abstract: Methods of treating kidney diseases or disorders and methods of identifying agents for treatment of kidney diseases or disorders are provided. The method includes administering to a subject in need thereof, an effective amount of an agent which inhibits myeloid progenitor cells in the subject from producing soluble urokinase receptor (suPAR). The method includes administering the agent to a patient, where the patient, has an increased number of Gr-1 low cells relative to a control.

Abstract: The disclosure provides pharmaceutical compositions including an oligonucleotide that down-regulates the over-expression of at least one miRNA of SEQ ID NOs: 1-283. The oligonucleotide may be complementary to the nucleotide sequence of at least one of SEQ ID NOs: 1-283, or hybridizes under stringent conditions to a nucleotide sequence of at least one of SEQ ID NOs: 1-283. Further provided are methods of diagnosing Parkinson's Disease (PD) in a subject. The methods may include detecting the level of expression of at least one miRNA of SEQ ID NOs: 1-283 in a biological sample from the subject, and comparing the level of expression in the sample to the level of expression in a reference. Further provided are methods for treating, preventing, or reducing the risk of PD. Kits are also provided.

Abstract: A method of treating a wound in a diabetic patient is provided. The method includes administering a therapeutically effective amount of Chemokine (C-C motif) ligand 2 (CCL2) to a wound site. In another aspect, a method of treating a wound in a diabetic patient is provided. The method includes assaying a level of CCL2 in the diabetic patient relative to a level of CCL2 in a normal subject and administering a therapeutically effective amount of CCL2 to the diabetic patient.

Abstract: One aspect of the invention provides a system for radiation treatment of a tumor allowing for imaging of the tumor and a surrounding region during radiation therapy and to methods of using such a system. In one embodiment, the system includes a number of radiation detectors positioned in an array to detect radiation scattered from the tumor and the surrounding region. A 3-dimensional image of the tumor is reconstructed from the 2-dimensional scattered radiation projections.

Abstract: This disclosure relates to pharmaceutical compositions useful for inhibiting the progression of urea cycle disorders and neurodegenerative disorders, such as Parkinson's disease, Alzheimer's disease, and multiple sclerosis. The pharmaceutical compositions may include glyceryl tribenzoate and glyceryl dibenzoate. The pharmaceutical compositions may be orally administered to the patient one time per day.

Abstract: Methods for measuring a panel of biomarkers in a subject suspected of having breast cancer are provided. The methods include obtaining a biological sample from the subject and determining a measurement for a panel of biomarkers in the biological sample, the panel comprising at least 5 biomarkers selected from the group comprising LPC(18:3), LPC(20:2), LPC(20:1), LPC(20:0), PC(32:1), PC(34:4), PC(38:3), PC(40:5), PC(40:3), PC(44:11), ePC(32:2), ePC(38:3), C19:1 CE, C19:0 CE, and C20:0 CE, wherein the measurement comprises measuring a level of each of the at least 5 biomarkers.

Abstract: Methods and compositions are disclosed to identify plasma and vitreous microRNA (miRNA) signatures of diabetic retinopathy (DR), and then as diagnostic biomarkers for the onset and progression of DR.

Abstract: Methods and kits are provided for collecting samples for assessment of circadian timing in a non-clinical environment. The methods include monitoring light exposure of a subject and placing a first biological sample in a first sample vial, wherein the first biological sample is obtained in the non-clinical environment in dim light comprising light less than about 50 lux and monitoring the use of the first sample vial with a monitoring device. The methods include placing a second biological sample from the subject in a second sample vial, the second biological sample being taking at a time interval after the first biological sample and monitoring the use of the second sample vial with the monitoring device. Kits include a photosensor, a plurality of sample vials free from labels, a label system for labeling the plurality of sample vials, and a monitoring device for monitoring use of the plurality of sample vials.

Abstract: Provided herein are methods for treatment of a neurodegenerative disease, such as neuronal ceroid lipofuscinosis including administering to a subject in need of such treatment a composition comprising a therapeutically effective amount of an agent that mediates upregulation of TPP1.

Abstract: A kit and/or method for use during surgery is configured to decrease the risk of accidental retention of foreign objects, such as surgical items or medical devices, used in surgery inside of a patient after the surgery is completed. Specifically, illustrative kits may include, but not be limited to, a combination of one or more foreign objects, an anchoring member attached to a point outside of the patient or surgical field, and at least one or more connection members connecting the foreign objects to the anchoring member. Illustrative methods may include, but not be limited to, anchoring one or more foreign object by one or more connection members, wherein a first end of each connection member is attached to the foreign object, and a second end of each connection member is attached to a junction member; attaching the junction member to an anchoring member; and attaching the anchoring member to a structure that is outside the patient or surgical field.

Abstract: An energy-releasing carbon nanotube transponder comprising a nanocapacitor connected to at least one carbon nanotube and method of using same are described. An adjustable amount of electric energy is stored within the nanocapacitor so that the energy-releasing carbon nanotube transponder delivers either a biologically destructive or a biologically non-destructive electrical charge to target cells in response to biological, chemical or electrical stimuli. An optional biocompatible coating onto the outer surface of the carbon nanotube transponder improves cellular targeting, cellular binding or body tolerance towards the carbon nanotube transponder. Optionally, a molecular label attached to at least one carbon nanotube allows for in vivo tracking of the carbon nanotube transponder.

Abstract: Methods of selecting a subject for treatment of amyotrophic lateral sclerosis (ALS) and methods of treatment for subjects having ALS or at risk of developing ALS are provided. The method of selecting subjects for treatment includes obtaining a biological sample from the subject, where the sample is obtained from the subject's gastrointestinal tract or skeletal muscle. The method further includes measuring a biomarker in the subject's sample and selecting the subject for treatment of ALS when the biomarker measurement in the subject's sample is lower or higher relative to a control measurement.

Abstract: A kit and/or method for use during surgery is configured to decrease the risk of accidental retention of foreign objects, such as surgical items or medical devices, used in surgery inside of a patient after the surgery is completed. Specifically, illustrative kits may include, but not be limited to, a combination of one or more foreign objects, an anchoring member attached to a point outside of the patient or surgical field, and at least one or more connection members connecting the foreign objects to the anchoring member. Illustrative methods may include, but not be limited to, anchoring one or more foreign object by one or more connection members, wherein a first end of each connection member is attached to the foreign object, and a second end of each connection member is attached to a junction member; attaching the junction member to an anchoring member; and attaching the anchoring member to a structure that is outside the patient or surgical field.

Abstract: Methods of treating kidney disease and protecting podocytes from injury are provided. Methods of screening agents for the treatment of kidney disease are also provided. In addition, methods of identifying structural or functional defects in a patient's podocytes and methods of identifying kidney disease causing agents in a patient's biological sample are also provided.

Abstract: A method and system for encouraging the selection of healthy products with a vending machine are provided. The method includes providing a vending machine that displays an inventory of products. Each product of the inventory of products includes a dispensing countdown time displayed on the vending machine. The method also includes receiving a first customer selection of a first product from the inventory of products, where the first product has a first dispensing countdown time. Additionally, the method includes actuating a countdown timer to count down to zero seconds from the first dispensing countdown time. The method also includes dispensing the first product once the countdown timer reaches zero seconds. The first product is only dispensed if a customer does not select a second product having a second dispensing countdown time before the first dispensing countdown time counts down to zero seconds.

Abstract: A method and a kit for assessing risk of lung cancer versus benign disease in a subject are provided. The method includes obtaining a biological sample from the subject and determining a measurement for a panel of biomarkers in the biological sample. The panel includes at least two biomarkers selected from the group consisting of IL-6, IL-1ra, IL-10, SDF-1?+?, TNF-?, MIP-1?, sIL-2R?, CA-125, sE-Selectin, Eotaxin, sEGFR, MMP-2, OPN, MCP-1, CRP, sICAM-1 and CYFRA 21.1. The method further includes comparing the measurement to a reference profile for the panel of biomarkers, sorting the subject into a group and determining whether the subject is at risk for lung cancer based on the group.

Abstract: Provided herein are methods for treatment of a neurodegenerative disease, such as neuronal ceroid lipofuscinosis including administering to a subject in need of such treatment a composition comprising a therapeutically effective amount of an agent that mediates upregulation of TPP 1.

Abstract: A method of a measuring kinematic parameter in a subject is provided. The method includes obtaining a first magnetic resonance (MR) image set of a bone marrow segment of the subject in a first position and obtaining a second MR image set of the bone marrow segment of the subject in a second position where the second position different from the first position. The method further includes registering the first image set with the second image set and measuring a kinematic parameter.

Abstract: An assay and a method for identifying a prebiotic to treat a subject in need thereof to promote intestinal barrier integrity or to blunt an inflammatory response are provided.

Abstract: A new class of anti-microbial agents and methods for preventing or reducing the risk of sexually transmitted infections and/or diseases is provided. Preferably, these anti-microbial agents are also contraceptive and, thus, also prevent or reduce the risk of unplanned pregnancies. The anti-microbial agents comprise a delivery vector having anti-microbial activity (and preferably contraceptive activity) coupled with a nitric oxide donor moiety.